- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
16 September: Results from the Phase 1/2 study in children aged 3-17 years have been published in The Lancet Infectious Diseases. The study conducted in China found that the Sinopharm vaccine is safe, well tolerated and stimulated a robust immune response after two doses. Phase 3 clinical trials assessing the vaccine efficacy against COVID-19 infections are ongoing.
20 August: The Sinopharm/Wuhan inactivated COVID-19 vaccine has been granted emergency use authorisation for 3-17-year-olds (in Chinese). The company states that data from Phase 1/2 clinical trials showed good immune response and no safety issues for people aged 3 to 17 years who received two-doses of the vaccine.
The vaccine was given emergency use authorisation in adults on 25 February 2021.
For more details on the vaccine see here.
Additional data provided by
English
Japanese
